Neurological Pain News & Research | Nerve Pain Treatment Studies



Featured Article

Latest News


FDA Approves Two New Strengths of Apadaz for Pain Management

Apadaz was initially approved in February 2018 as 6.12mg/325mg immediate-release tablets for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.